Description:
Technology Summary
Connexin hemichannel’s play a role in several disorders and diseases, including deafness, cataracts, and ischemic damage of the heart, brain, and kidneys. Aminoglycosides have been shown to inhibit these channels, but their antibiotic effects are problematic. This invention is comprised of several aminoglycoside derivatives that keep their beneficial channel inhibiting properties, but drop their problematic antibiotic effects, making them ideal candidates to be explored for pharmaceutical and therapeutic use.
Reference Number
D-1534
Market Applications
• Biomedical research
• Medicine
• Genetics
Features, Benefits & Advantages
• Increase in inhibitory properties of kanamycin A
• Loss of antibiotic properties of kanamycin A
• No longer have unwanted side effects because of antibiotic properties
• Low cytotoxicity
Intellectual Property
A provisional patent was filed on 6/12/2018, serial number 62683673
Development Stage
Compounds have been synthesized and tested, further characterization is being done with regard to dosing and delivery.
Researchers
Guillermo Altenberg, Department Chair of Cell Physiology and Molecular Biophysics, Texas Tech University Health Sciences Center
Cheng-Wei Chang, Professor of Organic Chemistry, Utah State University, Department of Chemistry and Biochemistry
Keywords
Aminoglycoside, kanamycin A, connexin, hemichannel, derivative, modulate, inhibitor